Literature DB >> 21565286

Epidemiology and management of refractory lupus nephritis.

Guillermo J Pons-Estel1, Rosa Serrano, Miguel A Plasín, Gerard Espinosa, Ricard Cervera.   

Abstract

Although the survival of patients with lupus nephritis (LN) has improved considerably in recent years, refractory LN appears in a substantial proportion of patients and, therefore, treatment of LN remains a real challenge today. We will use the term "refractory" LN, for those cases with none or partial response to first-line therapies. In this sense, numerous epidemiological factors, including racial, socioeconomic, histological and serological parameters, may influence treatment response and, therefore, may have an impact on the outcome of renal involvement. Initial conventional therapy will depend somewhat on these epidemiological factors. If this initial therapy fails, fortunately today we have alternative therapies that include the multitarget therapy and the use of biologics. Published evidence about these therapies is presented in this review. Important terms in the management of LN, such as the definition of complete response, partial response, sustained response and renal flare as well as the discrimination of different types of flare, are also discussed here according to the European consensus statement on the terminology used in the management of lupus glomerulonephritis.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21565286     DOI: 10.1016/j.autrev.2011.04.032

Source DB:  PubMed          Journal:  Autoimmun Rev        ISSN: 1568-9972            Impact factor:   9.754


  22 in total

1.  Commercial rodent diets differentially regulate autoimmune glomerulonephritis, epigenetics and microbiota in MRL/lpr mice.

Authors:  Michael R Edwards; Rujuan Dai; Bettina Heid; Thomas E Cecere; Deena Khan; Qinghui Mu; Catharine Cowan; Xin M Luo; S Ansar Ahmed
Journal:  Int Immunol       Date:  2017-06-01       Impact factor: 4.823

Review 2.  The long-term marriage between autoimmunity and internal medicine: a homage to Manuel Carlos Dias.

Authors:  Carlo Selmi; M Eric Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2012-12       Impact factor: 8.667

Review 3.  Autoimmunity in 2011.

Authors:  Carlo Selmi
Journal:  Clin Rev Allergy Immunol       Date:  2012-08       Impact factor: 8.667

4.  Allogeneic mesenchymal stem cell transplantation for lupus nephritis patients refractory to conventional therapy.

Authors:  Fei Gu; Dandan Wang; Huayong Zhang; Xuebing Feng; Gary S Gilkeson; Songtao Shi; Lingyun Sun
Journal:  Clin Rheumatol       Date:  2014-08-14       Impact factor: 2.980

Review 5.  A systems approach to renal inflammation in SLE.

Authors:  Celine C Berthier; Matthias Kretzler; Anne Davidson
Journal:  Clin Immunol       Date:  2016-08-14       Impact factor: 3.969

Review 6.  Lupus Nephritis: A Different Disease in European Patients?

Authors:  Vladimir Tesar; Zdenka Hruskova
Journal:  Kidney Dis (Basel)       Date:  2015-08-28

Review 7.  New Treatment Options in Lupus Nephritis.

Authors:  Pauline M Montigny; Frédéric A Houssiau
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2022-03-17       Impact factor: 4.291

Review 8.  Autoimmune-mediated renal disease and hypertension.

Authors:  Erika I Boesen; Rahul M Kakalij
Journal:  Clin Sci (Lond)       Date:  2021-09-17       Impact factor: 6.876

9.  Extracorporeal immunoadsorption of antibodies against the VRT-101 laminin epitope in systemic lupus erythematosus: a feasibility evaluation study.

Authors:  Alon Y Hershko; Anat Scheiman-Elazari; Suhail Aamar; Yaakov Naparstek
Journal:  Immunol Res       Date:  2013-07       Impact factor: 2.829

Review 10.  Lupus nephritis.

Authors:  Hans-Joachim Anders; Ramesh Saxena; Ming-Hui Zhao; Ioannis Parodis; Jane E Salmon; Chandra Mohan
Journal:  Nat Rev Dis Primers       Date:  2020-01-23       Impact factor: 52.329

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.